Article

A semi-quantitative, rapid, point of care SARS-CoV-2 serologic assay predicts neutralizing antibody levels

2023-06-01

Abstract excerpt

The ongoing COVID-19 pandemic has caused millions of deaths and the continued emergence of new variants suggests continued circulation in the human population. In the current time of vaccine availability and new therapeutic development, including antibody-based therapies, many questions about long-term immunity and protection remain uncertain. Identification of protective antibodies in individuals is often done us...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 4348d47c-2320-56c2-90b1-0908ef828ddb
DOI: 10.1101/2023.05.30.542314

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

A semi-quantitative, rapid, point of care SARS-CoV-2 serologic assay predicts neutralizing antibody levelsDOI 10.1101/2023.05.30.542314Read

Evaluation of a Rapid Semiquantitative Lateral Flow Assay for the Prediction of Serum Neutralizing Activity Against SARS-CoV-2 VariantsSemantic proximity Read

A point-of-care lateral flow assay for neutralising antibodies against SARS-CoV-2Semantic proximity Read

Robust correlations across six SARS‐CoV‐2 serology assays detecting distinct antibody featuresSemantic proximity Read

Longitudinal variation in SARS-CoV-2 antibody levels and emergence of viral variants: implications for the ability of serological assays to predict immunitySemantic proximity Read

Quantifying post-vaccination protective anti-SARS-CoV-2 IgG antibodies in blood and saliva with a fully automated, high throughput digital immunoassaySemantic proximity Read

Employment of a high-throughput functional assay to define the critical factors that influence vaccine-induced, cross-variant neutralizing antibodies for SARS-CoV-2.Semantic proximity Read

Use of the Lateral Flow Immunoassay to Characterize SARS-CoV-2 RBD-Specific Antibodies and Their Ability to React with the UK, SA and BR P.1 Variant RBDsSemantic proximity Read

IMMUNO-COV™ v2.0: Development and Validation of a High-Throughput Clinical Assay for Measuring SARS-CoV-2-Neutralizing Antibody TitersSemantic proximity Read

Development of a SARS-CoV-2 total antibody assay and the dynamics of antibody response over time in hospitalized and non-hospitalized patients with COVID-19Semantic proximity Read

Clinical performance of SARS-CoV-2 IgG antibody tests and potential protective immunitySemantic proximity Read

A Role for Nucleocapsid-Specific Antibody Function in COVID-19 Convalescent Plasma TherapySemantic proximity Read

Functional Antibodies in COVID-19 Convalescent PlasmaSemantic proximity Read